Skip to content
Subscriber Only

Roche Takes Another Shot at Alzheimer’s After Biogen Success

Updated on

Roche Holding AG is weighing a second test for an experimental Alzheimer’s drug that failed in an initial study, after a similar offering from Biogen Inc. showed promise in slowing the memory-robbing ailment.

Roche stopped a trial of gantenerumab in December because patients weren’t benefiting more than those receiving a placebo. Four months later, Biogen said that its drug slowed the progression of the disease, supporting a long-held hypothesis that targeting a protein linked to the telltale plaques found in the brains of Alzheimer’s patients may yield a treatment.